A pharmacological profile of intravenous amisulpride for the treatment of post-operative nausea and vomiting.

A pharmacological profile of intravenous amisulpride for the treatment of post-operative nausea and vomiting. Expert Rev Clin Pharmacol. 2020 Apr 03;: Authors: Fox G, Kranke P Abstract INTRODUCTION: The issue of post-operative nausea and vomiting (PONV) remains important in surgical practice, contributing to patient distress, slower recovery and increased use of healthcare resources. Many surgical patients report it to be a worse problem than pain. New antiemetics of different classes are still needed to help manage PONV effectively, especially the treatment of established PONV after the failure of common prophylactic antiemetics such as 5-HT3-antagonists and corticosteroids. Intravenous amisulpride, a drug with a long history of safe use in oral form as an antipsychotic, has recently been approved in the US (trade name: Barhemsys) as an intravenous antiemetic for the prevention and treatment of PONV.Areas covered: This review article summarises the published data on the clinical pharmacology, safety and efficacy of intravenous amisulpride as an antiemetic, supplemented by published data on oral amisulpride, where relevant to the intravenous form. Literature was obtained via the PubMed search terms "intravenous amisulpride" and "amisulpride AND safety". Both primary and secondary pharmacology are covered, along with clinical pharmacokinetics (distribution, metabolism and excretion). The review of clinical safety and efficacy includes...
Source: Pharmacological Reviews - Category: Drugs & Pharmacology Authors: Tags: Expert Rev Clin Pharmacol Source Type: research